Trial Profile
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Omega-3 carboxylic acids (Primary)
- Indications Hypertriglyceridaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 11 Apr 2020 Primary endpoint (Efficacy of AZD0585 by assessment of percent change in serum triglycerides) has been met, as per Results published in the Circulation Journal
- 11 Apr 2020 Results published in the Circulation Journal
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.